
A rigorous cost-benefit assessment can help to chart a cost-effective path forward.
James P. Catania is a managing consultant at Tunnell Consulting
A rigorous cost-benefit assessment can help to chart a cost-effective path forward.
Executive management leadership is essential in the effective implementation of QbD.
By identifying and eliminating non-value-added activities, drug manufacturers can avoid falling into the same cost-traps in the future.
Published: May 1st 2011 | Updated:
Published: March 1st 2011 | Updated:
Published: July 1st 2010 | Updated: